Select Publications
Conference Abstracts
2022, 'CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 15 - 15, http://dx.doi.org/10.26190/unsworks/28407
,2022, 'EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 14 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000864433100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S278 - S278, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900548&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S132 - S132, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, Vol. 71, http://dx.doi.org/10.2337/db22-862-P
,2022, 'FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease', in Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 37, http://dx.doi.org/10.1093/ndt/gfac126.002
,2022, 'POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION', in Kidney International Reports, Elsevier BV, Vol. 7, pp. S8 - S8, http://dx.doi.org/10.1016/j.ekir.2022.01.027
,2021, 'Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial', in DIABETOLOGIA, SPRINGER, Vol. 64, pp. 227 - 227, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696550100443&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial', in Diabetes, Obesity and Metabolism, Vol. 23, pp. 1652 - 1659, http://dx.doi.org/10.1111/dom.14386
,2021, 'A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 36, pp. 160 - 160, presented at 58th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA), ELECTR NETWORK, 05 June 2021 - 08 June 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713465600422&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus', in Metabolism, Elsevier, Vol. 116, pp. 154509, http://dx.doi.org/10.1016/j.metabol.2020.154509
,2020, 'GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)', in NEPHROLOGY, WILEY, Vol. 25, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO ALBUMINURIA AT BASELINE: RESULTS FROM PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE SERUM URATE LEVEL: RESULTS FROM POST HOC ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 60 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200190&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO DIABETIC KIDNEY DISEASE AT BASELINE: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 11 - 11
,2020, 'VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE', in NEPHROLOGY, WILEY, Vol. 25, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S269 - S269, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600560&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Effects of canagliflozin on cardiovascular death and hospitalisation for heart failure by eGFR: integrated analyses of the CANVAS Program and CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S267 - S268, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600558&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S61 - S62, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, http://dx.doi.org/10.26190/unsworks/27933
,2020, 'Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 3316 - 3316, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106303323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 1175 - 1175, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106301178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1120-P
,2020, 'Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1098-P
,2020, 'CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1336 - 1336, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101381&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1342 - 1342, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000562392101387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 35, pp. 1351 - 1351, presented at 57th ERA-EDTA Congress, ELECTR NETWORK, 06 June 2020 - 09 June 2020, http://dx.doi.org/10.1093/ndt/gfaa142|iii1351
,2020, 'CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1018 - 1018, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 1852 - 1852, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979101839&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 75, pp. 215 - 215, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), IL, Chicago, 28 March 2020 - 30 March 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000522979100211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S343 - S343, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S341 - S342, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S484 - S485, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303804096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme', in DIABETOLOGIA, SPRINGER, SPAIN, Barcelona, Vol. 62, pp. S340 - S341, presented at 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SPAIN, Barcelona, 16 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303803039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 206 - 206, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495412900569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 205 - U715, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495412900568&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, pp. 338 - 338, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495412901136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, HUNGARY, Budapest, Vol. 34, presented at 56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, HUNGARY, Budapest, 13 June 2019 - 16 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495412900567&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'FACTORS ASSOCIATED WITH REGRESSION OF LEFT VENTRICULAR MASS INDEX IN THE ACTIVE DIALYSIS TRIAL', in NEPHROLOGY, WILEY, Vol. 23, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'IMPACT OF EXTENDED HOURS DIALYSIS ON UTILITY-BASED QUALITY OF LIFE: RESULTS FROM THE ACTIVE DIALYSIS TRIAL', in NEPHROLOGY, WILEY, Vol. 23, pp. 11 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'RELATIVE CONTRIBUTIONS TO MAJOR DIALYSIS RANDOMISED CONTROLLED TRIALS FROM TEN GLOBAL REGIONS', in NEPHROLOGY, WILEY, Vol. 23, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'THE QUALITY OF LIFE IMPROVEMENTS ASSOCIATED WITH EXTENDED HOURS DIALYSIS ARE CONSISTENT ACROSS SUBGROUPS', in NEPHROLOGY, WILEY, Vol. 23, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000443138700064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, TX, Austin, Vol. 71, pp. 574 - 574, presented at Spring Clinical Meeting of the National-Kidney Foundation (NKD), TX, Austin, 10 April 2018 - 14 April 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000428167100243&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES: A SYSTEMATIC REVIEWAND META-ANALYSIS', in NEPHROLOGY, WILEY-BLACKWELL, Vol. 21, pp. 108 - 108, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, Vol. 54, pp. S23 - S23, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, Vol. 54, pp. S442 - S442, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671302285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'INTENSIVE GLUCOSE LOWERING AND END STAGE KIDNEY DISEASE - NEW DATA FROM THE ADVANCE TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, Vol. 16, pp. 42 - 42, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294977600072&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'NEW MODELS FOR THE PREDICTION OF EARLY AND LATE RENAL EVENTS IN TYPE 2 DIABETES', in NEPHROLOGY, WILEY-BLACKWELL, Vol. 16, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294977600144&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,